Peoples Financial Services CORP. Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Peoples Financial Services CORP. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,094 shares of the company’s stock after selling 269 shares during the quarter. Johnson & Johnson comprises 1.3% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 16th biggest position. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $2,906,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Floyd Financial Group LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $683,000. R.H. Investment Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $3,623,000. Pines Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $477,000. SeaCrest Wealth Management LLC raised its stake in Johnson & Johnson by 1.5% during the fourth quarter. SeaCrest Wealth Management LLC now owns 25,087 shares of the company’s stock worth $3,628,000 after purchasing an additional 374 shares during the period. Finally, Accurate Wealth Management LLC boosted its holdings in Johnson & Johnson by 8.4% in the 4th quarter. Accurate Wealth Management LLC now owns 23,214 shares of the company’s stock valued at $3,298,000 after purchasing an additional 1,806 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.0 %

JNJ opened at $144.74 on Thursday. The business has a fifty day moving average price of $149.12 and a 200 day moving average price of $156.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market capitalization of $348.48 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the firm earned $2.66 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. Johnson & Johnson’s payout ratio is 71.78%.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Finally, Bank of America restated a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.